16 assets in Thyroid Gland Papillary Carcinoma

Therapeutic assets addressing Thyroid Gland Papillary Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cobimetinib Thyroid Gland Papillary Carcinoma	Cancer Research UK	P2/3	B (56)
Dabrafenib Thyroid Gland Papillary Carcinoma	Cancer Research UK	P2/3	B (56)
Trametinib Thyroid Gland Papillary Carcinoma	Cancer Research UK	P2/3	B (56)
Vemurafenib Thyroid Gland Papillary Carcinoma	Cancer Research UK	P2/3	CCC (55)
Entrectinib Thyroid Gland Papillary Carcinoma	Hoffmann-La Roche	P2	CCC (53)
Fluorouracilum Thyroid Gland Papillary Carcinoma	Peking Union Medical College Hospital	P1/2	CCC (50)
Irinotecan Thyroid Gland Papillary Carcinoma	Peking Union Medical College Hospital	P1/2	CCC (50)
Amxt1501 Thyroid Gland Papillary Carcinoma	Aminex Therapeutics, Inc.	P1/2	CCC (48)
Atorvastatin Thyroid Gland Papillary Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Axitinib Thyroid Gland Papillary Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Eflornithine Thyroid Gland Papillary Carcinoma	Aminex Therapeutics, Inc.	P1/2	CCC (48)
Selpercatinib Thyroid Gland Papillary Carcinoma	Eli Lilly and Company	P1/2	CCC (48)
Toripalimab Thyroid Gland Papillary Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
ty-1091 Thyroid Gland Papillary Carcinoma	TYK Medicines, Inc	P1/2	CCC (48)
Cetuximab Thyroid Gland Papillary Carcinoma	Peking Union Medical College Hospital	N/A	D (30)
Oxaliplatin Thyroid Gland Papillary Carcinoma	Peking Union Medical College Hospital	N/A	D (30)